Gut hormones and appetite regulation.

Journal

Current opinion in endocrinology, diabetes, and obesity

ISSN: 1752-2978

Titre abrégé: Curr Opin Endocrinol Diabetes Obes

Pays: England

ID NLM: 101308636

Informations de publication

Date de publication:
22 Mar 2024

Historique:

medline: 21 3 2024

pubmed: 21 3 2024

entrez: 21 3 2024

Statut: aheadofprint

Résumé

Various gut hormones interact with the brain through delicate communication, thereby influencing appetite and subsequent changes in body weight. This review summarizes the effects of gut hormones on appetite, with a focus on recent research. Ghrelin is known as an orexigenic hormone, whereas glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), postprandial peptide YY (PYY), and oxyntomodulin (OXM) are known as anorexigenic hormones. Recent human studies have revealed that gut hormones act differently in various systems, including adipose tissue, beyond appetite and energy intake, and even involve in high-order thinking. Environmental factors including meal schedule, food contents and quality, type of exercise, and sleep deprivation also play a role in the influence of gut hormone on appetite, weight change, and obesity. Recently published studies have shown that retatrutide, a triple-agonist of GLP-1, GIP, and glucagon receptor, and orforglipron, a GLP-1 receptor partial agonist, are effective in weight loss and improving various metabolic parameters associated with obesity. Various gut hormones influence appetite, and several drugs targeting these receptors have been reported to exert positive effects on weight loss in humans. Given that diverse dietary and environmental factors affect the actions of gut hormones and appetite, there is a need for integrated and largescale long-term studies in this field.

Identifiants

DOI: 10.1097/MED.0000000000000859 PMID: 38511400

pubmed: 38511400

doi: 10.1097/MED.0000000000000859

pii: 01266029-990000000-00090

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Weltens N, Iven J, Van Oudenhove L, et al. The gut-brain axis in health neuroscience: implications for functional gastrointestinal disorders and appetite regulation. Ann N Y Acad Sci 2018; 1428:129–150.

Berthoud H-R, Albaugh VL, Neuhuber WL. Gut-brain communication and obesity: understanding functions of the vagus nerve. J Clin Invest 2021; 131:143770.

Roh E, Choi KM. Hormonal gut-brain signaling for the treatment of obesity. Int J Mol Sci 2023; 24:3384.

Aukan MI, Coutinho S, Pedersen SA, et al. Differences in gastrointestinal hormones and appetite ratings between individuals with and without obesity: a systematic review and meta-analysis. Obes Rev 2023; 24:e13531.

Richards P, Thornberry NA, Pinto S. The gut-brain axis: identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. Mol Metab 2021; 46:101175.

Wachsmuth HR, Weninger SN, Duca FA. Role of the gut–brain axis in energy and glucose metabolism. Exp Mol Med 2022; 54:377–392.

Duca FA, Waise TMZ, Peppler WT, et al. The metabolic impact of small intestinal nutrient sensing. Nat Commun 2021; 12:903.

Bany Bakar R, Reimann F, Gribble FM. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. Nat Rev Gastroenterol Hepatol 2023; 20:784–796.

Malik S, McGlone F, Bedrossian D, et al. Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab 2008; 7:400–409.

Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141:4255–4261.

Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194–198.

Muller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab 2015; 4:437–460.

Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714–1719.

Tschop M, Wawarta R, Riepl RL, et al. Postprandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24:RC19–RC21.

Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85:495–522.

Currie PJ, Mirza A, Fuld R, et al. Ghrelin is an orexigenic and metabolic signaling peptide in the arcuate and paraventricular nuclei. Am J Physiol Regul Integr Comp Physiol 2005; 289:R353–R358.

Garfield AS, Li C, Madara JC, et al. A neural basis for melanocortin-4 receptor-regulated appetite. Nat Neurosci 2015; 18:863–871.

Pietrzak M, Yngve A, Hamilton JP, et al. A randomized controlled experimental medicine study of ghrelin in value-based decision making. J Clin Invest 2023; 133:e168260.

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131–2157.

Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379:69–72.

Aldawsari M, Almadani FA, Almuhammadi N, et al. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes 2023; 16:575–595.

Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab 2021; 23: (Suppl 3): 5–29.

Adriaenssens AE, Biggs EK, Darwish T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab 2019; 30:987–996. e6.

Asmar M, Simonsen L, Madsbad S, et al. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 2010; 59:2160–2163.

Fan W, Ellacott KL, Halatchev IG, et al. Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat Neurosci 2004; 7:335–336.

Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650–654.

Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab 2014; 3:241–251.

Behary P, Alessimii H, Miras AD, et al. Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: a secondary analysis of a randomized single-blind placebo-controlled study. Diabetes Obes Metab 2023; 25:1731–1739.

Vujovic N, Piron MJ, Qian J, et al. Late isocaloric eating increases hunger, decreases energy expenditure, and modifies metabolic pathways in adults with overweight and obesity. Cell Metab 2022; 34:1486–1498. e7.

Carter S, Hill AM, Buckley JD, et al. Acute feeding with almonds compared to a carbohydrate-based snack improves appetite-regulating hormones with no effect on self-reported appetite sensations: a randomised controlled trial. Eur J Nutr 2023; 62:857–866.

Sommersten CH, Gjerde ES, Laupsa-Borge J, et al. Relationship between ketones, ghrelin, and, appetite on isocaloric diets with varying carbohydrate quality and amount: results from a randomized controlled trial in people with obesity (CARBFUNC). J Nutr 2023; 153:459–469.

Lauritsen JV, Bergmann N, Junker AE, et al. Oral glucose has little or no effect on appetite and satiety sensations despite a significant gastrointestinal response. Eur J Endocrinol 2023; 189:619–626.

Frampton J, Serrano-Contreras JI, Garcia-Perez I, et al. The metabolic interplay between dietary carbohydrate and exercise and its role in acute appetite regulation in males: a randomized controlled study. J Physiol 2023; 601:3461–3480.

Hu M, Kong Z, Shi Q, et al. Acute effect of high-intensity interval training versus moderate-intensity continuous training on appetite-regulating gut hormones in healthy adults: a systematic review and meta-analysis. Heliyon 2023; 9:e13129.

van Egmond LT, Meth EMS, Engstrom J, et al. Effects of acute sleep loss on leptin, ghrelin, and adiponectin in adults with healthy weight and obesity: a laboratory study. Obesity (Silver Spring) 2023; 31:635–641.

Feinle C, Grundy D, Otto B, et al. Relationship between increasing duodenal lipid doses, gastric perception, and plasma hormone levels in humans. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1217–R1223.

Jalleh RJ, Trahair LG, Wu T, et al. Effect of gastric distension with concurrent small intestinal saline or glucose infusion on incretin hormone secretion in healthy individuals: a randomized, controlled, crossover study. Diabetes Obes Metab 2023; 25:1849–1854.

Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022; 327:138–150.

Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with Type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015; 314:687–699.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 2016; 375:311–322.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med 2016; 375:1834–1844.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387:205–216.

Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes. N Engl J Med 2021; 385:503–515.

Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab 2022; 34:1234–1247. e9.

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity—a Phase 2 trial. N Engl J Med 2023; 389:514–526.

Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402:529–544.

Muller TD, Finan B, Clemmensen C, et al. The new biology and pharmacology of glucagon. Physiol Rev 2017; 97:721–766.

Mochiki E, Suzuki H, Takenoshita S, et al. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J Gastroenterol 1998; 33:835–841.

Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 2020; 117:29959–29967.

Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023; 389:877–888.

Day JW, Gelfanov V, Smiley D, et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 2012; 98:443–450.

Corbin KD, Carnero EA, Allerton TD, et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity (Silver Spring) 2023; 31:350–362.